Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Examining Tolerance to CNS Stimulants in ADHD
NCT02039908Phase 4
Key facts
- Status
- Completed
- Start
- Apr 2013
- Primary completion
- May 2018
- Countries
- 1
- Sponsor
- Florida International University
- Modality
- Small Molecules
- Drugs
- methylphenidate
- Conditions
- attention deficit hyperactivity disorder (ADHD)
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Florida International University. Primary endpoint: Number of Dose Changes Required Per Protocol at 10 months. Started Apr 2013; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Children with ADHD and IQ > 80, excluding those with other psychotropic meds, autism, or methylphenidate intolerance.
04
Endpoints
Primary
Number of Dose Changes Required Per Protocol
Secondary
Time to First Dose Increase
Beyond the preview
Go deeper on NCT02039908.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039908.